Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Cynthia B.E. Chee, Kyi-Win KhinMar, Li-H. Sng, Roland Jureen, Jeffery Cutter, Vernon J.M. Lee, Yee-Tang Wang. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?. Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017

Member's Comments

No comment yet.

Related content which might interest you: Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa Source: Eur Respir J, 51 (5) 1800544; 10.1183/13993003.00544-2018 Year: 2018 Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021 Death rates in patients during and after MDR-TB treatment in a semi rural area of South Africa Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011 Prognosis and outcome in patients with extremely drug resistant tuberculosis from the Western Cape province, South Africa Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Culture conversion rates of multi-drug resistant (MDR-TB) patients treated in the community versus an inpatient setting in a rural area of the Western Cape (WC) of South Africa Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea Source: Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019 Year: 2019 Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa Source: Eur Respir J, 51 (6) 1800017; 10.1183/13993003.00017-2018 Year: 2018 Primary drug resistance in HIV/tuberculosis patients in two large cities of Siberia Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 A retrospective analysis of quinolone prescriptions for tuberculosis in two North Birmingham hospitals Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 A follow up Study of TB patients put on DOTS from South India Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Prevalence and characteristic of drug-resistant tuberculosis patients in South Halmahera District, eastern Indonesia Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations Year: 2020 Drug resistant tuberculosis among Greek and immigrant patients in a pulmonary department in northern Greece Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Pattern of second line drug-resistance in MDR-TB treatment failure cases at a tertiary care tuberculosis treatment centre in western region of India Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 HIV screening in tuberculosis patients, in the northern region of Portugal Source: International Congress 2015 – Screening strategies in TB Year: 2015 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016